E-mail: zackova.daniela@fnbrno.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikovaná abstrakta
- ABNORMALITY OF GLUCOSE AND LIPID METABOLISM DURING NILOTINIB THERAPY – RESULTS OF ENIGMA 2 STUDY
- AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: STILL NOT OUT OF FASHION
- AUTONOMIC DYSFUNCTION IS AUGMENTED DURING THERAPY, BUT CAN BE IMPROVED BY PHYSICAL EXERCISE IN PATIENTS WITH HEMATOLOGICAL MALIGNANCY. RESULTS OF A PILOT TRIAL.
- CD26 ANTIGEN IS SPECIFIC FOR LEUKEMIC STEM CELLS IN CHRONIC MYELOID LEUKEMIA AND DISTINGUISHES PATIENT GROUPS WITH DIFFERENT RATIOS OF LEUKEMIC AND HEALTHY STEM CELL
- Comparison of Glucose and Lipid Metabolism Abnormality during Nilotinib, Imatinib and Dasatinib Therapy – Results of Enigma 2 Study
- DASATINIB EFFICACY AND TOLERANCE IN THE TREATMENT OF CHRONIC MYELOID LEUKEMIA (CML) PATIENTS RESISTANT/INTOLERANT TO IMATINIB IN THE CONTEXT OF REAL CLINICAL PRACTICE MANAGEMENT
- DETECTION OF AN ABERRANT FORM OF E13A2 BCR-ABL TRANSCRIPT CAUSING FAILURE OF MOLECULAR DIAGNOSTICS IN PATIENT WITH CHRONIC MYELOID LEUKEMIA (CML)
- EFFICACY AND SAFETY OF IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. AN ANALYSIS OF A COMPREHENSIVE POPULATION-BASED DATABASE
- ESTIMATION OF THE CURRENT SURVIVAL MEASURES IN CHRONIC MYELOID LEUKEMIA: METHODOLOGY AND NEW SOFTWARE TOOLS
- CHRONIC MYELOID LEUKEMIA: IS THE REAL PROGNOSIS OF NEWLY DIAGNOSED PATIENTS REALLY SO GOOD?
- IMATINIB (IMA) PLASMA CONCENTRATION (PC) MONITORING AND ITS CORRELATION WITH TREATMENT RESPONSE IN CHRONIC MYELOGENOUS LEUKEMIA (CML): A SINGLE CENTRE EXPERIENCE
- IMATINIB IN THE FIRST LINE CHRONIC MYELOID LEUKEMIA (CML) TREATMENT. CAN WE COMPARE THE REAL-LIFE DATA TO CLINICAL TRIAL RESULTS?
- IMATINIB IN THE FIRST-LINE CML TREATMENT: AN ANALYSIS OF A COMPREHENSIVE NON-COMMERCIAL DATABASE OF ALL CONSECUTIVE PATIENTS IN A DEFINED POPULATION
- IMPACT OF TREATMENT ADMINISTRATION ON SELECTION OF BCRABL1 KINASE DOMAIN MUTATIONS
- MECHANISM OF IMPAIRED GLUCOSE METABOLISM DURING NILOTINIB THERAPY IN PATIENTS WITH CHRONIC MYELOGENOUS LEUKEMIA
- Minimal Residual Resistance In CML: Stable BCR-ABL Gene Expression at Levels 0.01–0.1% (IS) In the Consecutive Samples May Be Associated with BCR-ABL Mutation Development and MMoR Lost In a Small Number of Tyrosine Kinase Inhibitor Responders
- NEUROMUSCULAR TOXICITY OF TYROSINE KINASE INHIBITORS IN THE THERAPY OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA
- P53 Inactivation and Genomic Aberrations in Relation to Imatinib Resistance in Chronic Myeloid Leukemia
- PREDICTION OF IMATINIB THERAPY RESPONSE: A ROLE OF INTRACELLULAR TRANSPORTERS HOCT-1 AND ABCB1
- QUALITY OF LIFE (QOL) IN PATIENTS WITH CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML) ON IMATINIB. A PILOT STUDY.
- SKIN ADVERSE EFFECTS OF TYROSINE KINASE INHIBITORS IN THE THERAPY OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA – SINGLE CENTRE EXPERIENCE
- T315I MUTATIONS ARE CLUSTERED WITH ADVANCED PHASES CONTRARY TO OTHER ABERRATIONS IN CML PATIENTS RESISTANT TO TKI THERAPY
- The EUTOS Survival Score Is Preferable over the Sokal Score for Prognosis of Long-Term Survival of Patients with Chronic Myeloid Leukemia
- The Gene Expressions of hOCT1 and ABCB1 Change During the Course of CML in Relation to Imatinib Therapy
- The Outcome of Unselected Patients with Chronic Myeloid Leukemia (CML) In Chronic Phase (CP) Treated with Imatinib In the First Line and the Prognostic Value of ELN Defined Responses – Population Based Analysis of 458 Patients Treated Between 2003–20
- The Plateau of BCR-ABL Transcript Level =;>0.1% May Select CML Patients in Complete Cytogenetic Remission for Mutation Analysis.
- THE PROSPECTIVE ANALYSIS OF LOW LEVEL BCR-ABL1 T315I MUTATION IN THE CD34+ CELLS OF DE NOVO CML PATIENTS
- VALIDATION OF A NEW PROGNOSTIC SCORE AIMED TO IDENTIFY THREE GROUPS WITH DIFFERENT PROBABILITIES OF DYING OF CHRONIC MYELOID LEUKAEMIA IN 1,120 PATIENTS WITH FIRST-LINE IMATINIB TREATMENT
